These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16208666)

  • 1. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis.
    Sweiss NJ; Welsch MJ; Curran JJ; Ellman MH
    Arthritis Rheum; 2005 Oct; 53(5):788-91. PubMed ID: 16208666
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory vertebral sarcoidosis responding to infliximab.
    Garg S; Garg K; Altaf M; Magaldi JA
    J Clin Rheumatol; 2008 Aug; 14(4):238-40. PubMed ID: 18766126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab.
    Jacobi A; Shuler G; Hertl M
    Br J Dermatol; 2005 Aug; 153(2):448-9. PubMed ID: 16086769
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion.
    Rosen T; Doherty C
    Dermatol Online J; 2007 Jul; 13(3):14. PubMed ID: 18328208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients.
    Sené T; Juillard C; Rybojad M; Cordoliani F; Lebbé C; Morel P; Tazi A; Guibal F
    J Am Acad Dermatol; 2012 Feb; 66(2):328-32. PubMed ID: 22243729
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab in a patient with refractory mucosal aphthosis.
    Jacobi A; Debus D; Schuler G; Hertl M
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):109-10. PubMed ID: 18181985
    [No Abstract]   [Full Text] [Related]  

  • 8. Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?
    Arnaud L; Sene D; Costedoat-Chalumeau N; Cacoub P; Chapelon-Abric C; Piette JC
    J Rheumatol; 2009 Feb; 36(2):462-3. PubMed ID: 19208587
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential biomarkers of monocyte/macrophage activity in a patient with sarcoidosis, treated with infliximab.
    Fang B; Bhagat S; Busch R; Parfrey H; Hall FC
    Rheumatology (Oxford); 2011 May; 50(5):992-4. PubMed ID: 21278065
    [No Abstract]   [Full Text] [Related]  

  • 10. Remission of photosensitivity following treatment of psoriasis vulgaris with tumour necrosis factor inhibitors.
    Viguier M; Jeanmougin M; Begon E; Verola O; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Sep; 157(3):625-7. PubMed ID: 17596163
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous sarcoidosis.
    Marchell RM; Judson MA
    Semin Respir Crit Care Med; 2010 Aug; 31(4):442-51. PubMed ID: 20665394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacologic treatment of sarcoidosis].
    Cîlţ C
    Pneumologia; 2005; 54(2):66-71. PubMed ID: 16536004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?
    Sweiss NJ; Baughman RP
    J Rheumatol; 2007 Nov; 34(11):2129-31. PubMed ID: 17985412
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sarcoidosis: changing insights in therapy].
    Kamphuis LS; van Laar JA; Kuijpers RW; Missotten T; Thio HB; van Hagen PM
    Ned Tijdschr Geneeskd; 2010; 154(47):A1685. PubMed ID: 21118599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab in the management of severe pemphigus vulgaris.
    Pardo J; Mercader P; Mahiques L; Sanchez-Carazo JL; Oliver V; Fortea JM
    Br J Dermatol; 2005 Jul; 153(1):222-3. PubMed ID: 16029365
    [No Abstract]   [Full Text] [Related]  

  • 16. TNF--a antagonists and sarcoidosis.
    Culver DA; Baughman RP
    QJM; 2011 Apr; 104(4):374. PubMed ID: 21278060
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy.
    Mallbris L; Ljungberg A; Hedblad MA; Larsson P; Ståhle-Bäckdahl M
    J Am Acad Dermatol; 2003 Feb; 48(2):290-3. PubMed ID: 12582407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of infliximab in cutaneous sarcoidosis.
    Meyerle JH; Shorr A
    J Drugs Dermatol; 2003 Aug; 2(4):413-4. PubMed ID: 12884466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulcerative cutaneous sarcoidosis responding to adalimumab.
    Philips MA; Lynch J; Azmi FH
    J Am Acad Dermatol; 2005 Nov; 53(5):917. PubMed ID: 16243166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.